Association of Paraoxonase 1 Gene Polymorphisms with Risk of Parkinson's Disease: a Meta-analysis

Overview

Journal J Hum Genet

Specialty Genetics

Date 2004 Sep 16

PMID 15368102

Citations 41

Authors

Elias Zintzaras

Georgios M Hadjigeorgiou

Affiliations

Soon will be listed here.

Abstract

Paraoxonase1 (PON1) gene polymorphisms were implicated as risk factors for Parkinson's disease (PD), but the results of case-control studies that investigated these associations were controversial. In order to provide an answer to these contradictory results, a meta-analysis of all available studies relating the PON1-55M/L and PON1-192Q/R polymorphisms to the risk of developing PD was conducted. The racial descent of the populations in these studies was Caucasian and Asian. The meta-analysis revealed that there was an association of the PON1-55M allele and the risk of developing PD relative to the L allele: fixed effects pooled odds ratio (OR)=1.32 [95%CI (1.10-1.59)]. In addition, there was evidence of association for the genotypic contrast PON1-55MM+LM relative to PON1-55LL: fixed effects OR=1.50 [95%CI (1.16-1.95)]. There was no significant association between PON1-192Q/R alleles and risk of developing PD: OR=1.09 [95%CI (0.93-1.26)]. There was no evidence for an association between the genotypic contrasts of PON1-192 and development of PD. The heterogeneity between studies and the publication bias were not significant ( P> or =0.10) in either polymorphism. Therefore, the pooled results of the meta-analysis supported that there was an association between PON1-55M/L polymorphism and PD and that PON1-192Q/R polymorphism was unlikely to be a major risk factor for susceptibility to PD.

Citing Articles

Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review).

Krol-Grzymala A, Sienkiewicz-Szlapka E, Fiedorowicz E, Rozmus D, Cieslinska A, Grzybowski A Int J Mol Sci. 2022; 23(17).

PMID: 36077520 PMC: 9456033. DOI: 10.3390/ijms231710123.

Pon1 Deficiency Promotes Trem2 Pathway-Mediated Microglial Phagocytosis and Inhibits Pro-inflammatory Cytokines Release In Vitro and In Vivo.

Zhang L, Dong W, Ma Y, Bai L, Zhang X, Sun C Mol Neurobiol. 2022; 59(7):4612-4629.

PMID: 35589918 DOI: 10.1007/s12035-022-02827-1.

HDL and Oxidation.

Zhang Q, Jiang Z, Xu Y Adv Exp Med Biol. 2022; 1377:63-77.

PMID: 35575921 DOI: 10.1007/978-981-19-1592-5_5.

HDL Accessory Proteins in Parkinson's Disease-Focusing on Clusterin (Apolipoprotein J) in Regard to Its Involvement in Pathology and Diagnostics-A Review.

Berdowska I, Matusiewicz M, Krzystek-Korpacka M Antioxidants (Basel). 2022; 11(3).

PMID: 35326174 PMC: 8944556. DOI: 10.3390/antiox11030524.

PON1 DNA methylation and neurobehavior in Mexican-American children with prenatal organophosphate exposure.

Huen K, Solomon O, Kogut K, Eskenazi B, Holland N Environ Int. 2018; 121(Pt 1):31-40.

PMID: 30172926 PMC: 6242297. DOI: 10.1016/j.envint.2018.08.044.

References

Lau J, Ioannidis J, Schmid C . Quantitative synthesis in systematic reviews. Ann Intern Med. 1998; 127(9):820-6. DOI: 10.7326/0003-4819-127-9-199711010-00008. View

Tan E, Khajavi M, Thornby J, NAGAMITSU S, Jankovic J, Ashizawa T . Variability and validity of polymorphism association studies in Parkinson's disease. Neurology. 2000; 55(4):533-8. DOI: 10.1212/wnl.55.4.533. View

HUMBERT R, Adler D, Disteche C, Hassett C, Omiecinski C, Furlong C . The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993; 3(1):73-6. DOI: 10.1038/ng0193-73. View

Ntais C, Polycarpou A, Ioannidis J . Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2003; 12(2):120-6. View

Taylor M, Le Couteur D, Mellick G, Board P . Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J Neural Transm (Vienna). 2000; 107(8-9):979-83. DOI: 10.1007/s007020070046. View

Akhmedova S, Yakimovsky A, Schwartz E . Paraoxonase 1 Met--Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci. 2001; 184(2):179-82. DOI: 10.1016/s0022-510x(01)00439-7. View

Carmine A, Buervenich S, Sydow O, Anvret M, Olson L . Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov Disord. 2002; 17(4):764-6. DOI: 10.1002/mds.10172. View

Whitehead A . A prospectively planned cumulative meta-analysis applied to a series of concurrent clinical trials. Stat Med. 1998; 16(24):2901-13. DOI: 10.1002/(sici)1097-0258(19971230)16:24<2901::aid-sim700>3.0.co;2-5. View

Warner T, Schapira A . Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S16-23; discussion S23-5. DOI: 10.1002/ana.10487. View

10.

Lau J, Antman E, Kupelnick B, Mosteller F, CHALMERS T . Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992; 327(4):248-54. DOI: 10.1056/NEJM199207233270406. View

11.

Adkins S, Gan K, Mody M, La Du B . Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993; 52(3):598-608. PMC: 1682165. View

12.

Le Couteur D, McLean A, Taylor M, Woodham B, Board P . Pesticides and Parkinson's disease. Biomed Pharmacother. 1999; 53(3):122-30. DOI: 10.1016/S0753-3322(99)80077-8. View

13.

Ioannidis J . Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998; 279(4):281-6. DOI: 10.1001/jama.279.4.281. View

14.

Mochizuki H, Scherer S, Xi T, Nickle D, Majer M, Huizenga J . Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene. 1998; 213(1-2):149-57. DOI: 10.1016/s0378-1119(98)00193-0. View

15.

Kondo I, Yamamoto M . Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 1998; 806(2):271-3. DOI: 10.1016/s0006-8993(98)00586-1. View

16.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

17.

MacLeod M, Lewis S, Dennis M . Effect of deprivation on time to hospital in acute stroke. J Neurol Neurosurg Psychiatry. 2003; 74(4):545-6. PMC: 1738409. DOI: 10.1136/jnnp.74.4.545. View

18.

Wheeler J, Keavney B, Watkins H, Collins R, Danesh J . Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 2004; 363(9410):689-95. DOI: 10.1016/S0140-6736(04)15642-0. View

19.

Akhmedova S, Anisimov S, Yakimovsky A, Schwartz E . Gln --> Arg 191 polymorphism of paraoxonase and Parkinson's disease. Hum Hered. 1999; 49(3):178-80. DOI: 10.1159/000022868. View

20.

Mackness B, Mackness M, Arrol S, Turkie W, Durrington P . Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997; 122(2):265-8. PMC: 1564940. DOI: 10.1038/sj.bjp.0701390. View